'The application of existing knowledge to the practical management of... ulcerative colitis is possible only if physicians and surgeons are willing to work together, preferably leaving the patient in one ward. ' F. Avery Jones (1952) Medical treatment of ulcerative colitis in the period 1934-1949 sorely tested the patience and optimism of both patient and doctor. Some principles remain as important today as they were then, a diet generous in protein and calories, mineral and iron replacement, and blood transfusion. Other aspects sound unfamiliar such as prolonged bed rest and a strict low-residue diet. Two advances around 1950 promised new hope and Avery Jones, with his unerring instinct for progress, marked them both. In 1950, the first encouraging results were described of treatment with the newly available hormones, cortisone and corticotrophin. Around the same time, Bryan Brooke was perfecting his new technique for construction of an ileostomy by manually everting the mucosa to bring it into apposition with skin.
Physicians and surgeons long frustrated by their relative ineffectiveness in treatment sensed success and joined forces with enthusiasm. Avery Jones invited his surgical colleagues at the Central Middlesex Hospital to treat colitis in medical wards. Conversely, in 1950 , the surgeons at St Mark's Hospital invited him to join them as Consulting Gastroenterologist and introduce new medical treatments there.
The advent of corticosteroids came at just the time when the concept of the controlled therapeutic trial was gaining force. By 1952, there were many anecdotal reports of improvement in colitis with cortisone and corticotrophin but, to quote Truelove and Witts (1954) , 'in none ... was there a formal trial in which some patients received therapy and some did not'. To remedy this uncertainty, these two had begun in 1952 a double-blind trial of cortisone against a dummy tablet 'to decide the issue'. They invited Avery Jones and Richard Doll, among others, to collaborate and the result was a classic of medical literature (Truelove and Witts, 1955) which proved the efficacy of cortisone beyond all doubt. Stimulated by this success, the same team, slightly enlarged, went on to compare the effectiveness of cortisone and corticotrophin in acute disease and to test the possible use of cortisone in prolonging remission (Truelove and Witts, 1959 (Isgar, Harman and Whorwell, 1983) . Prophylactic treatment with co-trimoxazole 2 tablets daily, seems well justified for a colitic who needs to travel in such areas (Dupont et al., 1983) . Similarly, antibiotics can cause diarrhoea, and even a form of mucosal inflammation, in normal subjects and their use needs especial care in a patient with colitis (Isgar et al., 1983) . There is also evidence that non-steroidal anti-inflammatory drugs may be associated with relapse (Rampton and Sladen, 1981; Rampton, McNeil and Sarner, 1983) or that some drugs such as mefenamic acid, may cause colitis (Hall et al., 1983; Phillips et al., 1983) . Even sulphasalazine seems to aggravate or cause colitis in a few patients (Schwartz et al., 1982; Adler, 1982) .
Although it is unlikely that colitis is due to psychological stress, clinical experience suggests that emotional factors can aggravate the disease.
Diet
There is no good evidence that the traditional low residue diet helps; conversely, there is little evidence that a high fibre intake is beneficial (Davies and Rhodes, 1978) (Berghouse et al., 1982) .
Intravenous corticosteroid therapy is indicated in severe acute colitis (Truelove et al., 1978) provided that an abdominal X-ray has excluded dilation of the colon and there is no other contra-indication to use of the drug. Response, if it is going to occur, is usually prompt. Some physicians (Truelove et (Ruddell et al., 1980) but the small volume (5 ml) generally used does not penetrate proximal to the sigmoid colon (Farthing, Rutland and Clark, 1979; Hay, Sharma and Irving, 1979) . Enemas of 100 ml always reach the sigmoid colon but upward spread to the descending and transverse colon is unpredictable. When topical treatment of colitis involving these areas is desired, it is worth adding barium to a therapeutic enema to check the level of penetration (Swarbrick, Loose and Lennard-Jones, 1974) and to see if the level can be affected by alteration in posture.
The convenient water-soluble esters, prednisolone 21-phosphate and betamethasone phosphate are both absorbed from the rectum though side effects are rare with the former. Prednisolone metasulphobenzoate produces lower prednisolone levels in the blood than the phosphate ester but the two esters are equally efficacious (Lee et al., 1980; McIntyre et al., 1984) . Similarly, beclomethasone dipropionate enemas are as effective as enemas containing 10 times the dose of betamethasone, yet without the evidence of corticosteroid side effects or adrenal suppresion seen with the latter (Kumana et al., 1982 (Baron et al., 1962b) , but also reduces the relapse rate when taken over a year by patients who are well . These results have been confirmed and extended by others (Dick et al., 1964; Dissanayake and Truelove, 1973) . The drug tends to act more slowly in acute disease than oral prednisone and with a higher incidence of side effects (Lennard-Jones et al., 1960; Truelove, Watkinson and Draper, 1962 ). Sulphasalazine appears safe to use throughout pregnancy and breast feeding (Jarnerot, 1981) .
Studies on the metabolism of sulphasalazine have shown that it is split by bacteria active in the colon to its two constituents, sulphapyridine and 5-aminosalicyclic acid (5ASA). Therapeutic experiments have shown that 5ASA is poorly absorbed from the colon and appears to be the active moiety by direct action on the mucosa (Azad Khan, Piris and Truelove, 1977) . The untoward effects of sulphasalazine, such as reversible infertility in men (Toovey et al., 1981) , dyspepsia, malaise, skin rash and occasional blood dyscrasias are all probably due to the sulphapyridine. New analogues which do not include a sulphonamide (Willoughby et al., 1982; Chan et al., 1983) and preparations of 5ASA itself designed to liberate the compound in the distal intestine or colon (Rasmussen et al., 1982; (Holdsworth, 1981) .
For distal acute disease, retention enemas (Palmer, Goepel and Holdsworth, 1981) (Dew et al., 1982 .
Any patient who has recovered from an attack of colitis should take sulphasalazine or a SASA preparation for at least a year. If a relapse occurs soon after stopping the drug, it seems reasonable to advise, and a patient will usually accept, the need to take a prophylactic dose for longer, even for many years.
Azathioprine
Azathioprine exerts a steroid-sparing effect in colitis (Rosenberg et al., 1975; Kirk and LennardJones, 1982) and probably has an intrinsic antiinflammatory action though this is hard to demonstrate (Jewell and Truelove, 1974 Ritchie, Powell-Tuck and Lennard-Jones, 1978 with permission of the publisher).
does not seem to have been fulfilled (Binder et a!., 1981) .
To date, there is no evidence that antibiotics benefit colitis (Davies et aL., 1977) . Anti-diarrhoeal drugs are not usually helpful (Engbaek et al., 1975) and may even cause trouble by leading to retention of hard stools in the normal colon proximal to the inflamed mucosa.
Conclusion
Over one professional lifetime, honoured in this volume, the survival rate of patients with colitis appears to have improved as Fig. 1 illustrates. Nutritional and drug therapy have become more effective; surgical treatment has become safer, and the indications for the various measures available are now better defined.
Progress has been made, but there is still much to do. We need more active, non-toxic and reliable drugs for use in the acute attack and, just as important, for the prevention of relapse. Surgery needs to move closer to its goal of a safe operation which removes all the diseased mucosa and yet gives a good predictable result without troublesome symptoms or a stoma.
